TY - JOUR
T1 - Novel Imaging Methods for Renal Mass Characterization
T2 - A Collaborative Review
AU - Roussel, Eduard
AU - Capitanio, Umberto
AU - Kutikov, Alexander
AU - Oosterwijk, Egbert
AU - Pedrosa, Ivan
AU - Rowe, Steven P.
AU - Gorin, Michael A.
N1 - Funding Information:
Financial disclosures: Eduard Roussel certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Eduard Roussel has received an unconditional research grant from Ipsen and Pfizer. Ivan Pedrosa served as a scientific advisor for both Bayer Healthcare and Merck, for which he received honoraria; served as a scientific advisor for Health Tech International, for which he received stock options; and is a coinventor of patents with Philips Healthcare, for which he receives no royalties. Steven Rowe receives salary support and serves as a consultant to Lantheus Medical Imaging, Inc.; owns stock in, has licensed patents to, and serves as a consultant to Precision Molecular, Inc.; and owns stock in and has licensed patents to Plenary AI, Inc. Michael Gorin serves as a paid consultant to Ambu A/S; Blue Earth Diagnostics, Inc; Corbin Clinical Resources, Inc. (Perineologic); Galvanize Therapeutics; KOELIS, Inc.; Lanthius Medical Imaging, Inc; and Simulated Inanimate Models, LLC. Dr. Gorin also has licensed a patent to Precision Molecular, Inc. for which he receives royalties and owns stock in Simulated Inanimate Models, Inc. All other authors have nothing to disclose.
Publisher Copyright:
© 2022 European Association of Urology
PY - 2022
Y1 - 2022
N2 - Context: The incidental detection of localized renal masses has been rising steadily, but a significant proportion of these tumors are benign or indolent and, in most cases, do not require treatment. At the present time, a majority of patients with an incidentally detected renal tumor undergo treatment for the presumption of cancer, leading to a significant number of unnecessary surgical interventions that can result in complications including loss of renal function. Thus, there exists a clinical need for improved tools to aid in the pretreatment characterization of renal tumors to inform patient management. Objective: To systematically review the evidence on noninvasive, imaging-based tools for solid renal mass characterization. Evidence acquisition: The MEDLINE database was systematically searched for relevant studies on novel imaging techniques and interpretative tools for the characterization of solid renal masses, published in the past 10 yr. Evidence synthesis: Over the past decade, several novel imaging tools have offered promise for the improved characterization of indeterminate renal masses. Technologies of particular note include multiparametric magnetic resonance imaging of the kidney, molecular imaging with targeted radiopharmaceutical agents, and use of radiomics as well as artificial intelligence to enhance the interpretation of imaging studies. Among these, 99mTc-sestamibi single photon emission computed tomography/computed tomography (CT) for the identification of benign renal oncocytomas and hybrid oncocytic chromophobe tumors, and positron emission tomography/CT imaging with radiolabeled girentuximab for the identification of clear cell renal cell carcinoma, are likely to be closest to implementation in clinical practice. Conclusions: A number of novel imaging tools stand poised to aid in the noninvasive characterization of indeterminate renal masses. In the future, these tools may aid in patient management by providing a comprehensive virtual biopsy, complete with information on tumor histology, underlying molecular abnormalities, and ultimately disease prognosis. Patient summary: Not all renal tumors require treatment, as a significant proportion are either benign or have limited metastatic potential. Several innovative imaging tools have shown promise for their ability to improve the characterization of renal tumors and provide guidance in terms of patient management.
AB - Context: The incidental detection of localized renal masses has been rising steadily, but a significant proportion of these tumors are benign or indolent and, in most cases, do not require treatment. At the present time, a majority of patients with an incidentally detected renal tumor undergo treatment for the presumption of cancer, leading to a significant number of unnecessary surgical interventions that can result in complications including loss of renal function. Thus, there exists a clinical need for improved tools to aid in the pretreatment characterization of renal tumors to inform patient management. Objective: To systematically review the evidence on noninvasive, imaging-based tools for solid renal mass characterization. Evidence acquisition: The MEDLINE database was systematically searched for relevant studies on novel imaging techniques and interpretative tools for the characterization of solid renal masses, published in the past 10 yr. Evidence synthesis: Over the past decade, several novel imaging tools have offered promise for the improved characterization of indeterminate renal masses. Technologies of particular note include multiparametric magnetic resonance imaging of the kidney, molecular imaging with targeted radiopharmaceutical agents, and use of radiomics as well as artificial intelligence to enhance the interpretation of imaging studies. Among these, 99mTc-sestamibi single photon emission computed tomography/computed tomography (CT) for the identification of benign renal oncocytomas and hybrid oncocytic chromophobe tumors, and positron emission tomography/CT imaging with radiolabeled girentuximab for the identification of clear cell renal cell carcinoma, are likely to be closest to implementation in clinical practice. Conclusions: A number of novel imaging tools stand poised to aid in the noninvasive characterization of indeterminate renal masses. In the future, these tools may aid in patient management by providing a comprehensive virtual biopsy, complete with information on tumor histology, underlying molecular abnormalities, and ultimately disease prognosis. Patient summary: Not all renal tumors require treatment, as a significant proportion are either benign or have limited metastatic potential. Several innovative imaging tools have shown promise for their ability to improve the characterization of renal tumors and provide guidance in terms of patient management.
KW - Tc-sestamibi
KW - Artificial intelligence
KW - Girentuximab
KW - Kidney cancer
KW - Machine learning
KW - Multiparametric magnetic resonance imaging
KW - PET
KW - Radiomics
KW - Renal cell carcinoma
KW - SPECT
KW - Virtual biopsy
UR - http://www.scopus.com/inward/record.url?scp=85125123597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125123597&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2022.01.040
DO - 10.1016/j.eururo.2022.01.040
M3 - Review article
C2 - 35216855
AN - SCOPUS:85125123597
JO - European Urology
JF - European Urology
SN - 0302-2838
ER -